# Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL

> **NCT05453669** · PHASE1 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 12 (estimated)

## Conditions studied

- B-cell Non-Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** CD19-CAR-DNT cells

## Key facts

- **NCT ID:** NCT05453669
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-15
- **Primary completion:** 2024-06
- **Final completion:** 2025-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2022-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05453669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05453669, "Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05453669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*